Oral Solids Market: By Dosage Form (Tablets (Conventional/Immediate Release, Modified Release, Chewable Tablets, and Effervescent Tablets), Capsules (Hard Gelatin Capsules, Soft Gelatin Capsules, and Others), Powders and Granules, Lozenges and Pastilles, and Gummies), By Drug Release Mechanism (Immediate Release, Delayed Release, Controlled Release), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets/Supermarkets), and Geography

Oral Solids Market size was valued at USD 142.8 billion in 2023 and is projected to reach USD 211.9 billion by 2030 is poised to grow at 4.9% CAGR from 2024-2030. The oral solids market is primarily propelled by the increasing demand for generic drugs, which offer cost-effective healthcare solutions. Oral solid dosage forms are preferred for their ease of manufacture, stability, and patient compliance, making them ideal for generic medications. Additionally, the aging global population, which necessitates long-term treatments for chronic diseases, also drives the market. Oral solid doses are convenient for this demographic, thus boosting the market. Furthermore, advancements in pharmaceutical formulations aimed at enhancing patient compliance and therapeutic outcomes are significant drivers.

Despite the growth, the market faces challenges such as stringent regulatory requirements that can delay product launches and increase costs. Intense competition among market players and supply chain management issues also pose significant constraints. Moreover, the complexity of developing oral solids for biologics, which are typically administered via injection, presents formulation challenges, the oral solids market is poised for continued growth, with opportunities arising in emerging markets, bioavailability enhancement technologies, and combination products are the opportunities in the market. Focus on patient-centric design, contract manufacturing, and sustainability are the trends in the oral solids market.

Oral Solids Market Key Developments:

• In Jan 2022, CordenPharma has indeed completed the acquisition of three Good Manufacturing Practice (GMP) facilities from Vifor Pharma. This strategic move will result in the renaming of these facilities to Corden Pharma Fribourg S.A. in Switzerland, which includes its Ettingen branch, and Corden Pharma Lisbon S.A. in Portugal.
• In Jan 2022, Catalent launched its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. This service integrates formulation development, on-demand clinical manufacturing, regulatory support, and clinical testing.